All Stories

  1. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients

    Article • Wiener klinische Wochenschrift, June 2023, Springer Science + Business Media

    Dr Aikaterini Bilitou

  2. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study

    Article • The Lancet Regional Health - Europe, June 2023, Elsevier

    Dr Aikaterini Bilitou

  3. Treatment and low-density lipoprotein cholesterol levels in patients with hypercholesterolaemia or mixed dyslipidaemia at high or very high cardiovascular risk: a population-based cross-sectional study in the Netherlands

    Article • Current Medical Research and Opinion, October 2022, Taylor & Francis

    Dr Aikaterini Bilitou

  4. Simulation study on LDL cholesterol target attainment, ASCVD events, and treatment cost of bempedoic acid in a representative German cohort of high- and very-high-CV risk patients

    Article • European Heart Journal, October 2022, Oxford University Press (OUP)

    Dr Aikaterini Bilitou

  5. Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients

    Article • European Heart Journal, October 2022, Oxford University Press (OUP)

    Dr Aikaterini Bilitou

  6. Importance of baseline LDL-C in the association between LDL-C lowering and cardiovascular risk: A meta-regression analysis

    Article • Atherosclerosis, August 2022, Elsevier

    Dr Aikaterini Bilitou

  7. Baseline characteristics and management of high- and very high-risk patients with hypercholesterolemia or mixed dyslipidemia in the multinational observational SANTORINI study

    Article • Atherosclerosis, August 2022, Elsevier

    Dr Aikaterini Bilitou

  8. Cardiovascular risk assessment by physicians and lipid-lowering therapy prescribing in high- and very high-risk patients: Results from the multinational observational santorini study

    Article • Atherosclerosis, August 2022, Elsevier

    Dr Aikaterini Bilitou

  9. Treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe: baseline demographics from the multinational observational SANTORINI study

    Article • European Heart Journal, October 2021, Oxford University Press (OUP)

    Dr Aikaterini Bilitou

  10. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study

    Article • Atherosclerosis Plus, September 2021, Elsevier

    Dr Aikaterini Bilitou

  11. A structured literature review of real world evidence reflecting the current lipid management across Europe

    Article • Atherosclerosis, August 2021, Elsevier

    Dr Aikaterini Bilitou

  12. CV4 Patients with Hypercholesterolaemia or MIXED Dyslipidaemia and High or VERY High Cardiovascular Risk According to ESC/EAS Guidelines – a Population-Based CROSS–Sectional Study from the Netherlands

    Article • Value in Health, December 2020, Elsevier

    Dr Aikaterini Bilitou

  13. Treatment patterns and healthcare resource use in primary hypercholesterolaemia and mixed dyslipidaemia: Results of a UK Delphi panel

    Article • Atherosclerosis, December 2020, Elsevier

    Dr Aikaterini Bilitou

  14. The prevalence and patient outcomes of adult primary hypercholesterolaemia and dyslipidaemia in the UK: a longitudinal retrospective study using a primary care dataset from 2008 to 2018

    Article • European Heart Journal, November 2020, Oxford University Press (OUP)

    Dr Aikaterini Bilitou

  15. Validated Instruments of Quality of Life (QOL) in Patients With Acute Myeloid Leukemia (AML) and Other Cancers

    Article • Frontiers in Pharmacology, July 2020, Frontiers

    Dr Aikaterini Bilitou

  16. Burden of Migraine in Europe Using Self-Reported Digital Diary Data from the Migraine Buddy© Application

    Article • Neurology and Therapy, October 2018, Springer Science + Business Media

    Dr Aikaterini Bilitou

  17. PND121 - UTILITIES ASSOCIATED WITH ATTRIBUTES OF MIGRAINE PREVENTIVE TREATMENTS: ROUTE OF ADMINISTRATION AND ADVERSE EVENTS

    Article • Value in Health, October 2018, Elsevier

    Dr Aikaterini Bilitou

  18. PND9 - MIGRAINE BURDEN BEFORE AND AFTER ERENUMAB TREATMENT: A RESPONDER ANALYSIS IN DIFFICULT-TO-TREAT PATIENTS

    Article • Value in Health, October 2018, Elsevier

    Dr Aikaterini Bilitou

  19. Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom

    Article • The Journal of Headache and Pain, September 2018, Springer Science + Business Media

    Dr Aikaterini Bilitou

  20. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective

    Article • American Journal of Cardiovascular Drugs, November 2016, Springer Science + Business Media

    Dr Aikaterini Bilitou

  21. Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece

    Article • ClinicoEconomics and Outcomes Research, October 2016, Dove Medical Press

    Professor John Parissis, Dr Aikaterini Bilitou

  22. Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting

    Article • Clinical Drug Investigation, September 2015, Springer Science + Business Media

    Dr Aikaterini Bilitou

  23. Annual budgetary impact of varenicline as part of a smoking cessation strategy in Greece

    Article • September 2015, European Respiratory Society (ERS)

    Dr Aikaterini Bilitou

  24. Patterns of pharmaceutical therapy in advanced melanoma.

    Article • Journal of Clinical Oncology, May 2013, American Society of Clinical Oncology (ASCO)

    Dr Aikaterini Bilitou

  25. Spatial and temporal expressions of prune reveal a role in Müller gliogenesis during Xenopus retinal development

    Article • Gene, November 2012, Elsevier

    Dr Aikaterini Bilitou

  26. The role of cell cycle in retinal development: Cyclin-dependent kinase inhibitors co-ordinate cell-cycle inhibition, cell-fate determination and differentiation in the developing retina

    Article • Developmental Dynamics, March 2010, Wiley

    Dr Aikaterini Bilitou

  27. 13-P091 Co-ordination of cell-cycle and cell fate determination in the Xenopus retina: An interplay of p27Xic1, Cyclin/cdks and NM23 proteins

    Article • Mechanisms of Development, August 2009, Elsevier

    Dr Aikaterini Bilitou

  28. The NM23 family in development

    Article • Molecular and Cellular Biochemistry, May 2009, Springer Science + Business Media

    Dr Aikaterini Bilitou

  29. Xenopus NM23-X4 regulates retinal gliogenesis through interaction with p27Xic1

    Article • Neural Development, January 2009, Springer Science + Business Media

    Dr Aikaterini Bilitou

  30. Visualising the dynamics of retinogenesis in a live vertebrate embryo

    Article • Developmental Biology, June 2007, Elsevier

    Dr Aikaterini Bilitou

  31. Transcriptional Repressor Erf Determines Extraembryonic Ectoderm Differentiation

    Article • Molecular and Cellular Biology, May 2007, ASM Journals

    Dr Aikaterini Bilitou